Skip to Content

Join the 'Restasis' group to help and get support from people like you.

Restasis News

A Reminder That Meds and Grapefruit Don't Always Mix

Posted 23 Jul 2017 by Drugs.com

SUNDAY, July 23, 2017 – If you like grapefruit juice, you need to be aware that it can affect the way some medications work, especially those used to treat high blood pressure or an irregular heart rhythm. That's the message from the U.S. Food and Drug Administration. The FDA requires some prescription and over-the-counter drugs taken by mouth to include warnings against drinking grapefruit juice or eating grapefruit while taking the drug. In most types of medications that interact with grapefruit juice, "the juice lets more of the drug enter the blood. When there is too much drug in the blood, you may have more side effects," the FDA's Shiew Mei Huang said in an agency news release. Examples of types of drugs that can be affected by grapefruit include: Cholesterol-lowering statin drugs, such as Zocor (simvastatin) and Lipitor (atorvastatin). High blood pressure drugs, such as ... Read more

Related support groups: High Blood Pressure, Hypertension, High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Grapefruit, Pravastatin, Allegra, Amiodarone, Zocor, Lovastatin, Fexofenadine, Restasis, Cyclosporine, Rosuvastatin, Allegra-D, Pravachol, Livalo

New Kidney Transplant Drug Cuts Risk of Earlier Death: Study

Posted 28 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – A newer drug used for preventing organ rejection might improve the long-term outlook for kidney transplant recipients, a new study finds. Over seven years, patients given the drug belatacept (brand name: Nulojix) were 43 percent less likely to die or see their donor kidney fail compared to patients given an older drug called cyclosporine. Experts said the findings should encourage more doctors and patients to choose belatacept over standard anti-rejection medications. "This is a potentially transformational drug," said study lead researcher Dr. Flavio Vincenti, a transplant specialist at the University of California, San Francisco. The study – funded by the drug's maker, Bristol-Myers Squibb – was published in the Jan. 28 issue of the New England Journal of Medicine. Belatacept was first approved by the U.S. Food and Drug Administration in 2011 for ... Read more

Related support groups: Renal Failure, Kidney Infections, Restasis, Cyclosporine, Chronic Kidney Disease, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Neoral, Organ Transplant - Rejection Reversal, Pyelonephritis, Renal Osteodystrophy, Graft-versus-host disease, Gengraf, Rejection Prophylaxis, Sandimmune, Nulojix, Hyperphosphatemia of Renal Failure, Belatacept

Ask a Question

Further Information

Related Condition Support Groups

Keratoconjunctivitis Sicca

Restasis Patient Information at Drugs.com